Page 53 - 《中国药房》2025年16期
P. 53
参考文献 [14] 中国抗癌协会癌症康复与姑息治疗专业委员会,中国抗
[ 1 ] BRAY F,LAVERSANNE M,SUNG H,et al. Global can‐ 癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支
cer statistics 2022:GLOBOCAN estimates of incidence 持治疗专业委员会,等. 中国抗肿瘤治疗相关恶心呕吐
and mortality worldwide for 36 cancers in 185 countries 预防和治疗指南:2023 版[J]. 中华肿瘤杂志,2024,46
[J]. CA Cancer J Clin,2024,74(3):229-263. (6):481-501.
[ 2 ] VASAN N,BASELGA J,HYMAN D M. A view on drug [15] 钱隽,郁韵秋. 液相色谱-质谱联用分析紫杉醇和多西他
resistance in cancer[J]. Nature,2019,575(7782):299-309. 赛中流动相体系的优化[J]. 复旦学报(医学版),2012,39
[ 3 ] 陈伟,王燕婷,王宇,等. 紫杉类抗肿瘤药物药学服务中 (6):605-610.
国专家共识[J]. 中国医院用药评价与分析,2022,22 [16] HAAK B W,LANKELMA J M,HUGENHOLTZ F,et al.
(12):1409-1427. Long-term impact of oral vancomycin,ciprofloxacin and
[ 4 ] RAPOPORT B L,HERRSTEDT J,SNOW R C,et al. metronidazole on the gut microbiota in healthy humans[J].
J Antimicrob Chemother,2019,74(3):782-786.
2023 updated MASCC/ESMO consensus recommenda‐
tions:prevention of nausea and vomiting following [17] GUO J,XU Y,CHEN L J,et al. Gut microbiota and host
multiple-day chemotherapy,high-dose chemotherapy,and CYP450s co-contribute to pharmacokinetic variability in
mice with non-alcoholic steatohepatitis:effects vary from
breakthrough nausea and vomiting[J]. Support Care Can‐
drug to drug[J]. J Adv Res,2022,39:319-332.
cer,2023,32(1):36.
[18] TOGAO M,KAWAKAMI K,OTSUKA J,et al. Effects of
[ 5 ] NATALE J J,SPINELLI T,CALCAGNILE S,et al. Drug-
drug interaction profile of components of a fixed combina‐ gut microbiota on in vivo metabolism and tissue accumula‐
tion of cytochrome P450 3A metabolized drug:midazolam
tion of netupitant and palonosetron:review of clinical data
[J]. Biopharm Drug Dispos,2020,41(7):275-282.
[J]. J Oncol Pharm Pract,2016,22(3):485-495.
[19] FLOWERS S A,BHAT S,LEE J C. Potential implications
[ 6 ] DEB S,HOPEFL R. Simulation of drug-drug interactions
of gut microbiota in drug pharmacokinetics and bioavai-
between breast cancer chemotherapeutic agents and anti‐
lability[J]. Pharmacotherapy,2020,40(7):704-712.
emetic drugs[J]. Daru,2023,31(2):95-105.
[ 7 ] DE MARTEL C,GEORGES D,BRAY F,et al. Global [20] AVIOR Y,LEVY G,ZIMERMAN M,et al. Microbial-
derived lithocholic acid and vitamin K2 drive the meta‐
burden of cancer attributable to infections in 2018:a
bolic maturation of pluripotent stem cells-derived and fe‐
worldwide incidence analysis[J]. Lancet Glob Health,
tal hepatocytes[J]. Hepatology,2015,62(1):265-278.
2020,8(2):e180-e190.
[21] ISHII M,TODA T,IKARASHI N,et al. Gastrectomy in‐
[ 8 ] LI X C,GUO X L,LIU Y X,et al. Antibiotics affect the creases the expression of hepatic cytochrome P450 3A by
pharmacokinetics of n-butylphthalide in vivo by altering
increasing lithocholic acid-producing enteric bacteria in
the intestinal microbiota[J]. PLoS One,2024,19(6):
mice[J]. Biol Pharm Bull,2014,37(2):298-305.
e0297713.
[22] WIKOFF W R,ANFORA A T,LIU J,et al. Metabolomics
[ 9 ] ZIMMERMANN M, ZIMMERMANN-KOGADEEVA
analysis reveals large effects of gut microflora on mamma‐
M,WEGMANN R,et al. Mapping human microbiome lian blood metabolites[J]. Proc Natl Acad Sci USA,2009,
drug metabolism by gut bacteria and their genes[J]. Na‐
106(10):3698-3703.
ture,2019,570(7762):462-467.
[23] MUN S J,LEE J,CHUNG K S,et al. Effect of microbial
[10] WALSH J,GHEORGHE C E,LYTE J M,et al. Gut
short-chain fatty acids on CYP3A4-mediated metabolic
microbiome-mediated modulation of hepatic cytochrome
activation of human pluripotent stem cell-derived liver or‐
P450 and P-glycoprotein:impact of butyrate and fructo- ganoids[J]. Cells,2021,10(1):126.
oligosaccharide-inulin[J]. J Pharm Pharmacol,2020,72 [24] BILEN M,DUFOUR J C,LAGIER J C,et al. The contri‐
(8):1072-1081. bution of culturomics to the repertoire of isolated human
[11] HUANG C,FENG S Y,HUO F J,et al. Effects of four an‐ bacterial and archaeal species[J]. Microbiome,2018,
tibiotics on the diversity of the intestinal microbiota[J]. 6(1):94.
Microbiol Spectr,2022,10(2):e0190421. [25] NATIVIDAD J M,AGUS A,PLANCHAIS J,et al. Im‐
[12] 陈怡琴,杨娇,裴文丽,等 . 黑逍遥散对 APP/PS1 小鼠认 paired aryl hydrocarbon receptor ligand production by the
知障碍及其肠道菌群的调节作用[J/OL]. 中国实验方剂 gut microbiota is a key factor in metabolic syndrome[J].
学杂志,2025:1-18[2025-06-11]. https://link.cnki.net/doi/ Cell Metab,2018,28(5):737-749.e4.
10.13422/j.cnki.syfjx.20250905. [26] ZHANG X T,HAN Y,HUANG W,et al. The influence of
[13] MANHAS D,BHATT S,RAI G,et al. Rottlerin renders a the gut microbiota on the bioavailability of oral drugs[J].
selective and highly potent CYP2C8 inhibition to impede Acta Pharm Sin B,2021,11(7):1789-1812.
EET formation for implication in cancer therapy[J]. Chem (收稿日期:2025-03-04 修回日期:2025-06-29)
Biol Interact,2023,380:110524. (编辑:张元媛)
中国药房 2025年第36卷第16期 China Pharmacy 2025 Vol. 36 No. 16 · 1999 ·

